Perspectives: Jellyfish Publication of an exciting new human clinical trial of proprietary KollaJell™ collagen peptide formulation
tennsun.com/10829236
Trending...
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
- Automation, innovation in healthcare processes featured at international conference in Atlanta
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports.
TEMECULA, Calif. - Tennsun -- Jellyfish Publication-Certified Nutraceuticals, Inc.
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on tennsun.com
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on tennsun.com
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on tennsun.com
- $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
- Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests
- Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
- OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
- Steve Everett Jr. Named President of L.T. Hampel Corporation
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on tennsun.com
- Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
- Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio
- MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
- Heartbeat Christian News Launches Chattanooga Edition, Kicking Off Nationwide Expansion
- Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Source: Certified Nutraceuticals, Inc.
0 Comments
Latest on tennsun.com
- UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
- Narcissist Apocalypse Marks 7 Years as a Leading Narcissistic Abuse Podcast
- High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
- CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- High-End Exterior House Painting in Boulder, Colorado
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
- Travis Koehler Writing Expands Strategic Resume Services
- CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
- ASR Media, Social T Marketing & PR Announce Merger
- $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI
- The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
- Ski Safety Awareness Month highlights why seeing clearly and wearing modern protection matters more than ever
- Vent Pros Expands Operations into Arizona to Meet Growing Demand for Commercial Ventilation and Kitchen Hood Cleaning Services


